The source protein for peptide IVDPGYLGY was interleukin-13 receptor subunit alpha-2 (IL13Rα2), which has been reported to be overexpressed in 85% of DIPG cases (63) and an effective CAR T-cell target for glioblastoma tumor regression (64). This evidence concerns the gene IL13RA2 and neoplasm.